十一月 2025
- Home
- Orna Therapeutics
十一月 2025的Orna Therapeutics市场份额分析
orna therapeutics is leaving linear thinking behind to create fully engineered circular rna (orna) therapeutics – an entirely new class of rna medicines.
Orna Therapeutics(包含公司地区分支机构)
查看更多网站流量和参与度信息- ornatx.com
Orna Therapeutics收入截至 十一月 2025为 25M - 50M
Orna Therapeutics主要域名产生的收入
3 年中Orna Therapeutics主要域名的收入
Orna Therapeutics主要域名的收入
Orna Therapeutics热门域名的总访问量
了解Orna Therapeutics市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Orna Therapeutics热门域名的平均访问时长
分析Orna Therapeutics参与度指标。
过去 3 个月的平均访问时长
子公司明细
Orna Therapeutics热门域名的平均页面浏览量
了解Orna Therapeutics如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Orna Therapeutics 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Orna Therapeutics, Inc. attended event 67th American Society of Hematology (ASH) Annual Meeting on Dec 6th '25.WATERTOWN, Mass., Dec. 7, 2025 - Orna Therapeutics (Orna), a biotechnology company dedicated to engineering immune cells in vivo to treat autoimmune and oncology diseases, today announced new preclinical data supporting the Company's in vivo CAR programs to target and treat a broad range of B cell-mediated autoimmune diseases and plasma cell or BCMA-related diseases at the 67th American Society of Hematology (ASH) Annual Meeting taking place in Orlando, Florida from December 6-9, 2025.
十二月 7, 2025阅读更多
新闻Orna Therapeutics, Inc. invests into assets: RNA delivery technology.ReNAgade Therapeutics also delivered a strategic exit when Orna Therapeutics acquired its RNA delivery technology in mid-2024.
七月 23, 2025阅读更多
新闻Orna Therapeutics, Inc. is developing RNA-based therapies in multiple myeloma.Orna Therapeutics and Shanghai Simnova have announced an expansion of their strategic collaboration to develop RNA-based therapies in multiple myeloma.
一月 17, 2025阅读更多
查看 Orna Therapeutics 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。